中国药师
中國藥師
중국약사
CHINA PHARMACIST
2014年
5期
806-807
,共2页
帕金森病%吡贝地尔%多巴丝肼
帕金森病%吡貝地爾%多巴絲肼
파금삼병%필패지이%다파사정
Parkinson's disease%Piribedil%Madopar
目的：观察吡贝地尔联合多巴丝肼治疗帕金森病的疗效和安全性。方法：58例帕金森病患者随机分为对照组和观察组，两组各29例，其中对照组单用多巴丝肼，观察组在对照组基础上加用吡贝地尔，连续治疗6个月后，采用帕金森病症状评分量表( UPDRS)进行疗效评定。结果：治疗6个月后观察组UPDRS运动评分较治疗前降低，降低程度优于对照组，两组治疗前后评分差值比较有统计学意义(P<0.05)；观察组总有效率为89.7%，明显高于对照组的65.5%(P<0.05)。结论：吡贝地尔联合多巴丝肼治疗帕金森病较单用多巴丝肼疗效更佳，安全性好，值得临床推广应用。
目的：觀察吡貝地爾聯閤多巴絲肼治療帕金森病的療效和安全性。方法：58例帕金森病患者隨機分為對照組和觀察組，兩組各29例，其中對照組單用多巴絲肼，觀察組在對照組基礎上加用吡貝地爾，連續治療6箇月後，採用帕金森病癥狀評分量錶( UPDRS)進行療效評定。結果：治療6箇月後觀察組UPDRS運動評分較治療前降低，降低程度優于對照組，兩組治療前後評分差值比較有統計學意義(P<0.05)；觀察組總有效率為89.7%，明顯高于對照組的65.5%(P<0.05)。結論：吡貝地爾聯閤多巴絲肼治療帕金森病較單用多巴絲肼療效更佳，安全性好，值得臨床推廣應用。
목적：관찰필패지이연합다파사정치료파금삼병적료효화안전성。방법：58례파금삼병환자수궤분위대조조화관찰조，량조각29례，기중대조조단용다파사정，관찰조재대조조기출상가용필패지이，련속치료6개월후，채용파금삼병증상평분량표( UPDRS)진행료효평정。결과：치료6개월후관찰조UPDRS운동평분교치료전강저，강저정도우우대조조，량조치료전후평분차치비교유통계학의의(P<0.05)；관찰조총유효솔위89.7%，명현고우대조조적65.5%(P<0.05)。결론：필패지이연합다파사정치료파금삼병교단용다파사정료효경가，안전성호，치득림상추엄응용。
Objective:To observe the clinical effect of piribedil and madopar on Parkinson's disease ( PD) . Methods:Totally 58 patients with PD were divided randomly into the treatment group (29 cases) and the control group (29 cases). Piribedil and madopar were used in the treatment group, while only madopar was applied in the control group. Therapeutic effect of both groups was evaluated by UPDRS at the end of 6 courses. Results:The decrease of UPDRS after the remedy in the treatment group was more significant than that in the control group (P<0. 05), and the total effective rate in the treatment group(89. 7%) was significantly higher than that in the control group(65. 5%)(P<0. 05). Conclusion:The clinical effect of piribedil combined with madopar on PD is superior to that of madopar alone, therefore, the combination use is a useful method in the treatment of PD with the value of popularization and applica-tion.
